Search Results - "FIGURSKI, Michal J"

Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC–MS/MS Reference Method by Korecka, Magdalena, Figurski, Michal J, Landau, Susan M, Brylska, Magdalena, Alexander, Jacob, Blennow, Kaj, Zetterberg, Henrik, Jagust, William J, Trojanowski, John Q, Shaw, Leslie M

“…Abstract Background Cerebrospinal fluid (CSF) amyloid-β1-42 (Aβ42) reliably detects brain amyloidosis based on its high concordance with plaque burden at…”
Get full text

High-Performance Liquid Chromatography-Mass Spectroscopy/Mass Spectroscopy Method for Simultaneous Quantification of Total or Free Fraction of Mycophenolic Acid and its Glucuronide Metabolites by FIGURSKI, Michal J, KORECKA, Magdalena, FIELDS, Leona, WALIGORSKA, Teresa, SHAW, Leslie M

“…Measurement of unbound fractions of mycophenolic acid and its metabolites may prove useful in explaining the complicated pharmacokinetic and pharmacodynamic…”
Get full text

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans by Kang, Ju-Hee, Korecka, Magdalena, Figurski, Michal J, Toledo, Jon B, Blennow, Kaj, Zetterberg, Henrik, Waligorska, Teresa, Brylska, Magdalena, Fields, Leona, Shah, Nirali, Soares, Holly, Dean, Robert A, Vanderstichele, Hugo, Petersen, Ronald C, Aisen, Paul S, Saykin, Andrew J, Weiner, Michael W, Trojanowski, John Q, Shaw, Leslie M

“…Abstract Introduction We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF)…”
Get full text

Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients by Figurski, Michal J, Waligórska, Teresa, Toledo, Jon, Vanderstichele, Hugo, Korecka, Magdalena, Lee, Virginia M.Y, Trojanowski, John Q, Shaw, Leslie M

“…Abstract Background The interassay variability and inconsistency of plasma β-amyloid (Aβ) measurements among centers are major factors precluding the…”
Get full text

Prospective quality-control monitoring in the context of a clinical trial by Figurski, Michal J, Waligórska, Teresa, Brylska, Magdalena, Korecka, Magdalena, Fields, Leona, Shah, Nirali, Pan, Sarah, Siemers, Eric R, Lachno, David R, Deckard, Deanilee, Dean, Robert A, Trojanowski, John Q, Shaw, Leslie M

Get full text

Development of a Predictive Limited Sampling Strategy for Estimation of Mycophenolic Acid Area Under the Concentration Time Curve in Patients Receiving Concomitant Sirolimus or Cyclosporine by FIGURSKI, Michal J, NAWROCKI, Artur, PESCOVITZ, Mark D, BOUW, Rene, SHAW, Leslie M

“…Limited sampling strategies for estimation of the area under the concentration time curve (AUC) for mycophenolic acid (MPA) co-administered with sirolimus…”
Get full text

Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters by Figurski, Michał J, Pawiński, Tomasz, Goldberg, Lee R, DeNofrio, David, Nawrocki, Artur, Taylor, David O, Lake, Kathleen D, Chojnowski, Donna, Shaw, Leslie M

“…Mycophenolate mofetil is a commonly used immunosuppressant in heart transplantation but pharmacokinetic monitoring is not routinely done. We performed a…”
Get full text

Web‐based requisitioning, tracking and laboratory result reporting system for clinical trials using a central laboratory: Biomarkers (non‐neuroimaging)/Use in clinical trial design and evaluation by Figurski, Michal J., Berlas, Shaila, Korecka, Magdalena, Foroud, Tatiana M., Galasko, Doug R., Shaw, Leslie M.

“…Abstract Background Chemical biomarkers are increasingly important in clinical trials. Many multi‐center trials use single core laboratory to process…”
Get full text

Web‐based requisitioning, tracking and laboratory result reporting system for clinical trials using a central laboratory by Figurski, Michal J., Berlas, Shaila, Korecka, Magdalena, Foroud, Tatiana M., Galasko, Doug R., Shaw, Leslie M.

“…Background Chemical biomarkers are increasingly important in clinical trials. Many multi‐center trials use single core laboratory to process biomarkers, to…”
Get full text

STANDARDIZATION OF AMYLOID BETA 42 IN-HOUSE CALIBRATORS FOR A REFERENCE LC-MS-MS METHOD FOR ANALYSIS OF AMYLOID BETA 42 IN HUMAN CSF, USING THREE AVAILABLE CERTIFIED REFERENCE MATERIALS by Korecka, Magdalena, Figurski, Michal J., Trojanowski, John Q., Shaw, Leslie M.

Get full text

P3‐232: VALIDATION STUDIES OF NEUROFILAMENT LIGHT AND Aβ‐40 AND Aβ‐42 ASSAYS IN HUMAN PLASMA USING THE SIMOA PLATFORM by Waligorska, Teresa, Figurski, Michal J., Jeromin, Andreas, Chen-Plotkin, Alice, Trojanowski, John Q., Shaw, Leslie M.

Get full text

P1‐265: STANDARDIZATION OF AMYLOID BETA 42 IN‐HOUSE CALIBRATORS FOR A REFERENCE LC‐MS‐MS METHOD FOR ANALYSIS OF AMYLOID BETA 42 IN HUMAN CSF, USING THREE AVAILABLE CERTIFIED REFERENCE MATERIALS by Korecka, Magdalena, Figurski, Michal J., Trojanowski, John Q., Shaw, Leslie M.

Get full text

VALIDATION STUDIES OF NEUROFILAMENT LIGHT AND Aβ-40 AND Aβ-42 ASSAYS IN HUMAN PLASMA USING THE SIMOA PLATFORM by Waligorska, Teresa, Figurski, Michal J., Jeromin, Andreas, Chen-Plotkin, Alice, Trojanowski, John Q., Shaw, Leslie M.

Get full text

P2‐091: ASSAY PERFORMANCE MONITORING FOR AD BIOMARKERS USING POOLED CEREBROSPINAL FLUID by Figurski, Michal J., Waligorska, Teresa, Korecka, Magdalena, Brylska, Magdalena, Alexander, Jacob, Shaw, Leslie M.

Get full text

ASSAY PERFORMANCE MONITORING FOR AD BIOMARKERS USING POOLED CEREBROSPINAL FLUID by Figurski, Michal J., Waligorska, Teresa, Korecka, Magdalena, Brylska, Magdalena, Alexander, Jacob, Shaw, Leslie M.

Get full text

ANALYTICAL AND CLINICAL PERFORMANCE OF AMYLOID BETA PEPTIDES: MEASUREMENT IN CSF OF ADNI2 AND GO PARTICIPANTS BY A LC-MS-MS REFERENCE METHOD by Korecka, Magdalena, Figurski, Michal J., Brylska, Magdalena, Alexander, Jackob, Trojanowski, John Q., Zetterberg, Henrik, Blennow, Kaj, Shaw, Leslie M.

Get full text

P1‐255: ANALYTICAL AND CLINICAL PERFORMANCE OF AMYLOID BETA PEPTIDES: MEASUREMENT IN CSF OF ADNI2 AND GO PARTICIPANTS BY A LC‐MS‐MS REFERENCE METHOD by Korecka, Magdalena, Figurski, Michal J., Brylska, Magdalena, Alexander, Jackob, Trojanowski, John Q., Zetterberg, Henrik, Blennow, Kaj, Shaw, Leslie M.

Get full text

DERIVING A CUT-OFF FOR THE ELECSYS® β-AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER’S DISEASE (AD) by Shaw, Leslie M., Waligorska, Teresa, Fields, Leona, Korecka, Magdalena, Figurski, Michal J., Trojanowski, John Q., Eichenlaub, Udo, Wahl, Simone, Quan, Marian, Lachno, David Richard, Talbot, Jayne A., Andersen, Scott W., Siemers, Eric R., Dean, Robert A.

Get full text

P1‐119: Prospective quality‐control monitoring in the context of a clinical trial by Figurski, Michal J., Waligórska, Teresa, Brylska, Magdalena, Korecka, Magdalena, Fields, Leona, Shah, Nirali, Pan, Sarah, Siemers, Eric R., Lachno, David R., Deckard, Deanilee, Dean, Robert A., Trojanowski, John Q., Shaw, Leslie M.

Get full text

Investigation of manganese-doped iron ammonia synthesis catalysts by Figurski, Michał J., Arabczyk, Walerian, Lendzion-Bieluń, Zofia, Lenart, Stanisław

“…The iron catalysts for ammonia synthesis doped with manganese in amounts up to 3 wt.% has been investigated. The addition of manganese oxide did not influence…”
Get full text